Why Retatrutide Is Dosed Once Weekly: Half-Life and Trial Design

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 10 sources cited · Author: FormBlends Editorial

Key Takeaways

• All published retatrutide trials use once-weekly subcutaneous dosing
• The plasma half-life is approximately 6 days, engineered through albumin-binding fatty-acid modification
• Weekly dosing produces stable plasma concentrations after several weeks of regular administration
• Retatrutide is investigational and not FDA-approved; weekly is the trial schedule, not a label
• FormBlends does not sell or supply retatrutide. Discuss any treatment plan with a licensed clinician

Direct answer

Retatrutide is dosed once weekly by subcutaneous injection in all published clinical trials. The molecule has an approximately 6-day plasma half-life, achieved through fatty-acid modification that binds serum albumin and slows clearance. Once-weekly dosing maintains pharmacologically active concentrations across the full week and is consistent with how semaglutide and tirzepatide are dosed. Retatrutide is investigational and not FDA-approved. Discuss any treatment with a licensed clinician.

Table of contents

1. Once-weekly across every retatrutide trial
2. The half-life and what enables it
3. Plasma concentration at weekly steady state
4. Why weekly was the design target
5. How weekly interacts with side-effect profile
6. Missed-dose handling in trial protocols
7. Comparison with other weekly GLP-1 medications
8. The future of even-longer-acting GLP-1 dosing
9. Contrary view: would less frequent be better?
10. Decision framework
11. FAQ
12. Sources

Once-weekly across every retatrutide trial

Retatrutide trial design has consistently used once-weekly subcutaneous administration. Specific trials include:

Trial	Indication	Schedule	Duration
Phase 1 (Coskun, Urva)	Healthy adults, T2D	Single dose; multiple ascending doses weekly	Weeks
Phase 2 obesity (Jastreboff 2023)	Obesity	Once weekly	48 weeks
Phase 2 T2D (Rosenstock 2023)	Type 2 diabetes	Once weekly	36 weeks
Phase 2 MASLD (Sanyal 2024)	Liver disease	Once weekly	48 weeks
TRIUMPH-1 (NCT05882045)	Obesity	Once weekly	Up to 88 weeks
TRIUMPH-2	T2D	Once weekly	52 weeks

Daily injection has never been part of retatrutide development. The molecule was designed for weekly dosing from the outset.

The half-life and what enables it

Retatrutide's structure is a chimeric peptide based on the glucagon family. The native peptides (GLP-1, GIP, glucagon) have half-lives measured in minutes; native GLP-1 is cleared in roughly 2-3 minutes by the enzyme DPP-4. To make a once-weekly drug, three modifications were applied:

• Amino acid substitutions to prevent DPP-4 cleavage
• A fatty-acid side chain that binds serum albumin reversibly, dramatically extending circulation time
• Modifications to the C-terminus that further reduce renal clearance

The same playbook was used for semaglutide (palmitic acid linker) and tirzepatide (fatty diacid linker). Retatrutide uses a related approach. The result is a half-life of approximately 6 days, sufficient to support weekly dosing with stable plasma exposure.

Plasma concentration at weekly steady state

With a 6-day half-life and weekly dosing, plasma concentration accumulates over the first 5-6 weeks of regular administration and then plateaus. Once at steady state, the trough concentration (right before the next dose) is roughly 50% of the peak concentration (a day or two after each dose). This range is narrow enough that pharmacologic activity is sustained across the whole week.

This is why the first month of dosing feels different from the steady state. The first dose only produces a single-dose curve; by week 6, every injection lands on top of residual drug from previous doses. Subjective response (appetite suppression, satiety, side effects) generally tracks this accumulation, with effects intensifying over the first few weeks of any given dose.

Why weekly was the design target

Once-weekly dosing has clear advantages over daily for an obesity medication:

• Adherence is much higher with weekly than daily regimens, particularly across 12+ months of use
• Cold-chain logistics are easier with weekly pens than daily ones
• The molecule's mechanism (slowed gastric emptying, central satiety effects) does not require minute-by-minute drug levels
• Weekly aligns with the existing commercial GLP-1 ecosystem, reducing patient learning curve

The downside is dose precision. A weekly injection delivers a larger bolus than a daily one would, which can increase the magnitude of early side effects in the days following each dose. This is one reason careful titration matters more for weekly long-half-life GLP-1s than for shorter-acting analogues.

How weekly interacts with side-effect profile

In the phase 2 trial, side effects clustered in patterns consistent with weekly dosing kinetics:

• Nausea most pronounced in the 1-3 days after each injection, easing as plasma concentration declined toward trough
• GI symptoms most severe in the week following a dose increase, when peak concentration rose above the previous level
• Tolerance development over 2-4 weeks at a steady dose, even though plasma concentration had reached steady state

This means most patients had a recognizable weekly rhythm: somewhat worse symptoms post-injection, gradually settling. The weekly schedule produces this pattern; a daily schedule would smooth it out at the cost of more total injections.

Missed-dose handling in trial protocols

The phase 2 protocol allowed missed doses to be administered within a defined window of the original scheduled day. The specifics typical of long-half-life GLP-1 protocols:

• If the missed dose can be given within roughly 3-4 days of the scheduled day, administer and resume the original schedule
• If the next scheduled dose is closer than that, skip the missed dose and continue on schedule
• Do not double a dose to make up for a missed one

This mirrors the labeled missed-dose handling for Wegovy and Zepbound. The long half-life means that minor schedule disruption does not meaningfully change plasma concentration, but doubling doses can produce undesirable peaks.

Comparison with other weekly GLP-1 medications

Medication	Approximate half-life	Schedule	FDA status
Retatrutide	~6 days	Once weekly	Investigational
Semaglutide (Ozempic, Wegovy)	~7 days	Once weekly	Approved
Tirzepatide (Mounjaro, Zepbound)	~5 days	Once weekly	Approved
Dulaglutide (Trulicity)	~5 days	Once weekly	Approved (T2D)
Liraglutide (Saxenda, Victoza)	~13 hours	Once daily	Approved

Retatrutide sits comfortably in the weekly GLP-1 family on pharmacokinetic terms. The differences across these drugs are receptor profile and potency, not dosing frequency.

The future of even-longer-acting GLP-1 dosing

Several monthly or quarterly GLP-1 candidates are in earlier development across the industry. None has produced enough trial data to compete on outcomes with weekly molecules yet. For the next several years, weekly will remain the dominant schedule for GLP-1 obesity medications.

Retatrutide is not being developed as a less-frequent regimen. The phase 3 (TRIUMPH) program continues to test weekly dosing.

Contrary view: would less frequent be better?

An argument for biweekly or monthly retatrutide: longer dosing intervals would smooth out the post-injection symptom peak, improve adherence even further, and reduce injection burden. The pharmacokinetics would in principle allow it.

The objections:

• No trial has tested biweekly or monthly retatrutide. Inferring efficacy from the weekly data is speculative.
• Larger doses at longer intervals produce higher peak concentrations, potentially worsening rather than improving the peak symptom experience.
• Multi-dose vial economics work better with weekly than less-frequent regimens.
• Patient-level adherence to a monthly schedule may not be better than to a weekly one when missed doses produce larger gaps in coverage.

For now, weekly is what the evidence supports. Less-frequent dosing is an open research question.

Decision framework

If you are evaluating retatrutide: the trial schedule is once weekly. There is no clinically validated alternative schedule. Retatrutide is investigational and not available through approved consumer channels.

If you are on an FDA-approved weekly GLP-1: your weekly schedule is governed by the FDA label. Missed-dose handling specifics are in the prescribing information for your medication.

If you are comparing schedules: weekly is standard across the modern GLP-1 obesity class. The exceptions are daily liraglutide (older) and once-daily oral semaglutide (Rybelsus, an FDA-approved oral form).

Discuss with a licensed clinician.

What to verify before using this answer

The useful next step for Why Retatrutide Is Dosed Once Weekly: Half-Life and Trial Design is to verify the details that can change the decision: current labeling, insurance rules, pharmacy instructions, dose timing, contraindications, and whether the evidence applies to your diagnosis rather than only to weight loss headlines.

For this retatrutide evidence page, the most relevant search terms are retatrutide, weekly, dose. Those terms point to a practical decision, so the answer should be checked against a current prescription label, payer policy, trial result, or clinician recommendation before you act.

FormBlends keeps this page focused on patient-level decision points: what is known, what is uncertain, what should be handled by a licensed clinician, and what should be avoided because it creates dosing, safety, or access risk.

FAQ

Is retatrutide once-weekly? Yes, in all published trials. Phase 2 and phase 3 use weekly subcutaneous dosing.

What is the half-life? Approximately 6 days based on published phase 1 pharmacokinetic work.

Why does half-life matter? A weekly schedule requires a half-life long enough to maintain active concentrations between doses. Six days is sufficient.

Could it be dosed less often? Theoretically plausible for some patients but unstudied. Weekly is the only schedule with efficacy data.

Could it be dosed more often? Would not improve efficacy at steady state and would increase injection burden.

Does the day matter? No specific day; just consistency. Patients pick a day and stay on it.

What if I miss a dose? Trial protocols typically allow administering within a few days. Beyond that window, skip and resume.

Is retatrutide FDA-approved? No. The weekly schedule is from clinical trials, not from a label.

Related guides

• What Is the Half-Life of Retatrutide? The Pharmacokinetic Story
• Retatrutide Once Weekly Dosing Schedule
• Splitting a Weekly Retatrutide Dose: The Misconception
• How Long Is Retatrutide Stable Once Reconstituted? What Peptide Stability Principles Suggest
• Retatrutide and Quality of Life Improvements
• Retatrutide at 6 Months: Half-Year Progress
• Tool: dosage calculator

Sources

1. Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity. NEJM. 2023.
2. Rosenstock J et al. Retatrutide in Type 2 Diabetes: A Phase 2 Trial. The Lancet. 2023.
3. Sanyal AJ et al. Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease. Nature Medicine. 2024.
4. Coskun T et al. LY3437943 (retatrutide), a novel triple GLP-1/GIP/glucagon receptor agonist. Cell Metabolism. 2022.
5. Urva S et al. Pharmacokinetics and pharmacodynamics of retatrutide in healthy adults. Diabetes, Obesity and Metabolism. 2023.
6. ClinicalTrials.gov NCT05882045 (TRIUMPH-1).
7. FDA Prescribing Information for Wegovy (semaglutide).
8. FDA Prescribing Information for Zepbound (tirzepatide).
9. Lau J et al. Discovery of the once-weekly GLP-1 analogue semaglutide. Journal of Medicinal Chemistry. 2015.
10. FDA Drug Approvals Database (no retatrutide approval as of May 2026).

Footer disclaimers

Platform Disclaimer. FormBlends connects patients to independent licensed providers and U.S.-based pharmacies. Retatrutide is investigational and not FDA-approved. FormBlends does not sell, supply, or prescribe retatrutide. This article describes published clinical-trial dosing.

Compounded Medication Notice. For medications other than retatrutide, FormBlends works with state-licensed 503A compounding pharmacies. Compounded GLP-1 preparations are not FDA-approved and are not interchangeable with branded drugs. Dosing schedules for compounded medications are determined by individual clinicians and pharmacies.

Results Disclaimer. The half-life and pharmacokinetic data cited in this article come from published phase 1 work in adults. Individual patient parameters may differ. The weekly dosing schedule is the trial protocol, not a personal recommendation.

Trademark Notice. Retatrutide is an investigational compound developed by Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Trulicity is a registered trademark of Eli Lilly. Saxenda and Victoza are registered trademarks of Novo Nordisk. Rybelsus is a registered trademark of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by any company referenced.